Robyn Karnauskas
Stock Analyst at Truist Securities
(2.42)
# 3,020
Out of 5,182 analysts
177
Total ratings
43.42%
Success rate
0.1%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $927.03 | +27.50% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.01 | +149.38% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $355.30 | -16.13% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $60.17 | +8.03% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $119.07 | -7.62% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $137.64 | -39.70% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $208.38 | +0.78% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $2.21 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $177.35 | +91.71% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $0.60 | +4,211.77% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.98 | +253.54% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $750.57 | +51.22% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.64 | +509.76% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.58 | +151.40% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $29.83 | -22.90% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $29.30 | +63.82% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $24.25 | +106.19% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $441.20 | +15.14% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $27.56 | +30.62% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $72.43 | -65.48% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.15 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $54.64 | +156.22% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $2.25 | +1,333,233.33% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.39 | +403.60% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $17.58 | +212.86% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $8.94 | +3,481.42% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $44.90 | -66.59% | 5 | Aug 9, 2022 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $927.03
Upside: +27.50%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.01
Upside: +149.38%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $355.30
Upside: -16.13%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $60.17
Upside: +8.03%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $119.07
Upside: -7.62%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $137.64
Upside: -39.70%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $208.38
Upside: +0.78%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.21
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $177.35
Upside: +91.71%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $0.60
Upside: +4,211.77%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.98
Upside: +253.54%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $750.57
Upside: +51.22%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.64
Upside: +509.76%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.58
Upside: +151.40%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $29.83
Upside: -22.90%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $29.30
Upside: +63.82%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $24.25
Upside: +106.19%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $441.20
Upside: +15.14%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $27.56
Upside: +30.62%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $72.43
Upside: -65.48%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.15
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $54.64
Upside: +156.22%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $2.25
Upside: +1,333,233.33%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.39
Upside: +403.60%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $17.58
Upside: +212.86%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $8.94
Upside: +3,481.42%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $44.90
Upside: -66.59%